Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 89

1.

Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?

Nixon AB, Schalper KA, Jacobs I, Potluri S, Wang IM, Fleener C.

J Immunother Cancer. 2019 Nov 27;7(1):325. doi: 10.1186/s40425-019-0799-2. Review.

2.

Comparison of dietary intakes of Canadian Armed Forces personnel consuming field rations in acute hot, cold, and temperate conditions with standardized infantry activities.

Ahmed M, Mandic I, Lou W, Goodman L, Jacobs I, L'Abbé MR.

Mil Med Res. 2019 Aug 16;6(1):26. doi: 10.1186/s40779-019-0216-7.

3.

Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics.

Anderson KC, Landgren O, Arend RC, Chou J, Jacobs IA.

Future Oncol. 2019 Oct;15(28):3267-3281. doi: 10.2217/fon-2019-0368. Epub 2019 Aug 9.

4.

Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma.

Noel M, O'Reilly EM, Wolpin BM, Ryan DP, Bullock AJ, Britten CD, Linehan DC, Belt BA, Gamelin EC, Ganguly B, Yin D, Joh T, Jacobs IA, Taylor CT, Lowery MA.

Invest New Drugs. 2019 Jul 12. doi: 10.1007/s10637-019-00830-3. [Epub ahead of print]

PMID:
31297636
5.

Potential of Biosimilars to Increase Access to Biologics: Considerations for Advanced Practice Providers in Oncology.

Tinsley SM, Grande C, Olson K, Plato L, Jacobs I.

J Adv Pract Oncol. 2018 Nov-Dec;9(7):699-716. Epub 2018 Nov 1. Review.

6.

Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial.

Johnson ML, Braiteh F, Grilley-Olson JE, Chou J, Davda J, Forgie A, Li R, Jacobs I, Kazazi F, Hu-Lieskovan S.

JAMA Oncol. 2019 Jul 1;5(7):999-1007. doi: 10.1001/jamaoncol.2019.0836.

7.

The effects of exercise and ambient temperature on dietary intake, appetite sensation, and appetite regulating hormone concentrations.

Mandic I, Ahmed M, Rhind S, Goodman L, L'Abbe M, Jacobs I.

Nutr Metab (Lond). 2019 May 6;16:29. doi: 10.1186/s12986-019-0348-5. eCollection 2019.

8.

Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics.

Davda J, Declerck P, Hu-Lieskovan S, Hickling TP, Jacobs IA, Chou J, Salek-Ardakani S, Kraynov E.

J Immunother Cancer. 2019 Apr 15;7(1):105. doi: 10.1186/s40425-019-0586-0. Review.

9.

Emerging therapeutic targets for patients with advanced prostate cancer.

Saad F, Shore N, Zhang T, Sharma S, Cho HK, Jacobs IA.

Cancer Treat Rev. 2019 Jun;76:1-9. doi: 10.1016/j.ctrv.2019.03.002. Epub 2019 Mar 19. Review.

PMID:
30913454
10.

Bispecific Antibodies in the Treatment of Hematologic Malignancies.

Duell J, Lammers PE, Djuretic I, Chunyk AG, Alekar S, Jacobs I, Gill S.

Clin Pharmacol Ther. 2019 Oct;106(4):781-791. doi: 10.1002/cpt.1396. Epub 2019 Mar 29. Review.

11.

Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone.

Engellau J, Seeger L, Grimer R, Henshaw R, Gelderblom H, Choy E, Chawla S, Reichardt P, O'Neal M, Feng A, Jacobs I, Roberts ZJ, Braun A, Bach BA.

World J Surg Oncol. 2018 Sep 19;16(1):191. doi: 10.1186/s12957-018-1478-3.

12.

Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America.

Scheinberg M, Pineda C, Castañeda-Hernández G, Zarbá JJ, Damião A, Arantes LH Jr, Jacobs I.

MAbs. 2018 Aug/Sep;10(6):827-842. doi: 10.1080/19420862.2018.1484977. Epub 2018 Aug 29. Review.

13.

Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer.

Lammers PE, Dank M, Masetti R, Abbas R, Hilton F, Coppola J, Jacobs I.

Br J Cancer. 2018 Aug;119(3):266-273. doi: 10.1038/s41416-018-0147-1. Epub 2018 Jul 13.

14.

An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.

Falchi L, Ferrajoli A, Jacobs I, Nava-Parada P.

Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):508-518.e14. doi: 10.1016/j.clml.2018.05.009. Epub 2018 May 23. Review.

15.

Global Acceptance of Biosimilars: Importance of Regulatory Consistency, Education, and Trust.

Cazap E, Jacobs I, McBride A, Popovian R, Sikora K.

Oncologist. 2018 Oct;23(10):1188-1198. doi: 10.1634/theoncologist.2017-0671. Epub 2018 May 16. Review.

16.

Bevacizumab biosimilars: scientific justification for extrapolation of indications.

Melosky B, Reardon DA, Nixon AB, Subramanian J, Bair AH, Jacobs I.

Future Oncol. 2018 Oct;14(24):2507-2520. doi: 10.2217/fon-2018-0051. Epub 2018 Apr 25. Review.

17.

Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future.

Carrascosa JM, Jacobs I, Petersel D, Strohal R.

Dermatol Ther (Heidelb). 2018 Jun;8(2):173-194. doi: 10.1007/s13555-018-0230-9. Epub 2018 Mar 16. Review.

18.

The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer.

Blackwell K, Gligorov J, Jacobs I, Twelves C.

Clin Breast Cancer. 2018 Apr;18(2):95-113. doi: 10.1016/j.clbc.2018.01.006. Epub 2018 Feb 2. Review.

19.

The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars.

Brown JR, Cymbalista F, Sharman J, Jacobs I, Nava-Parada P, Mato A.

Oncologist. 2018 Mar;23(3):288-296. doi: 10.1634/theoncologist.2017-0150. Epub 2017 Dec 6. Review.

20.

Drug tendering: drug supply and shortage implications for the uptake of biosimilars.

Dranitsaris G, Jacobs I, Kirchhoff C, Popovian R, Shane LG.

Clinicoecon Outcomes Res. 2017 Sep 29;9:573-584. doi: 10.2147/CEOR.S140063. eCollection 2017. Review.

Supplemental Content

Loading ...
Support Center